Genetically based atrial fibrillation: Current considerations for diagnosis and management

Authors, Journal, Affiliations, Type, DOI

• Authors: Anthony V. Pensa, Jayson R. Baman, Megan J. Puckelwartz, Jane E. Wilcox
• Journal: Journal of Cardiovascular Electrophysiology (2022), Volume 33, pp. 1944–1953
• Affiliations: Department of Medicine and Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
• Type: Invited Review
• DOI: https://doi.org/10.1111/jce.15446

Overview

This invited review from Northwestern University synthesises the genetic architecture of AF across three methodological levels — linkage analyses (rare familial variants), GWAS (>100 common variant loci), and single gene analyses (TTN, SCN5A, KCNQ1) — and examines how each level of genetic variation modifies AF risk, treatment response, and prognosis. A 5-criterion patient selection framework for genetic testing is proposed. Evidence is reviewed showing that GWAS loci (particularly 4q25 rs2200733) modulate catheter ablation outcomes, and the GENETIC-AF trial is highlighted as the first prospective genotype-guided AF pharmacotherapy trial. Written in 2022, the review predates the 2023 ACC/AHA Class IIb recommendation and reflects the then-current Class IIb guidance for familial AF only.

Keywords

Atrial fibrillation • Catheter ablation • Dilated cardiomyopathy • Genetic testing • Genome-wide association study • Polygenic risk score

Key Takeaways

Genetic Basis of AF — Three Methodological Layers

Linkage Analysis (Familial Rare Variants)

• Multiple rare GOF and LOF variants in ion channel genes, transcription factors, and structural/sarcomere proteins have been identified in multigenerational AF families
• KCNQ1: LOF → LQT syndrome type 1; GOF → early-onset AF with normal QTc and LV dilation
• Heritability of AF estimated at 62% in monozygotic twins; 22.1% from common variants in a European cohort (irrespective of age/sex)
• Linkage analyses are limited to familial/early-onset AF (<40–45 years); variants identified represent only a fraction of total AF burden

GWAS (Common Variants)

• 100 loci with genome-wide significance for AF risk identified to date; majority studied in European ancestry populations

• Key loci: 4q25 (PITX2 — strongest and most replicated across ancestries; regulates pulmonary vein development and L-type Ca²⁺/delayed rectifier K⁺ currents); ZFHX3 (16q22); TBX5; KCNQ1; angiotensinogen (AGT)
• Largest multiethnic meta-analysis (>500,000 participants, 84% European): 97 loci; 67 novel in combined ancestry; 3 European-specific; effect estimates similar across ancestries for top associations
• Hispanic/Latino cohort: only PITX2 replicated from 9 tested SNPs — highlighting ancestry-specific heterogeneity
• European ancestry subjects have increased AF risk vs. African, Asian, and Hispanic ancestry subjects — likely reflecting different risk allele frequencies, not simply ascertainment bias

Single Gene Analyses and Polygenic Risk

• In early-onset AF, ~10% have an identifiable variant associated with inherited arrhythmia or cardiomyopathy; odds of disease-associated variant increase 25% per decade at earlier AF diagnosis
• SCN5A: Associated with AF in both lone AF and structural heart disease AF context; also underlies LQT3, Brugada syndrome, and familial DCM
• TTN: TTNtv in 25% of familial DCM, linked to increased VA risk; high AF rates in TTN DCM; TTNtv associated with AF even controlling for cardiomyopathy status; TTNtv in familial AF cohort → median AF onset age 26; carriers had no echocardiographic LV dysfunction or LA/LV dilation at diagnosis or follow-up — consistent with atrial myopathy preceding structural change
• PRS: Top 2.5% of AF PRS scorers (FinnGen biobank) have 61% predicted lifetime risk of AF; higher PRS modifies AF risk independently of traditional risk factors (UK Biobank); PRS also modifies AF risk in TTNtv carriers (higher PRS → higher AF risk)

Patient Selection for Genetic Testing — 5-Criterion Framework

The authors propose genetic testing be considered for:

1. Lone AF: <66 years at AF diagnosis in the absence of structural heart disease
2. AF without classical risk factors (hypertension, CKD, diabetes)
3. AF + family history of ICD implantation
4. AF + family history of sudden cardiac death
5. AF + multigenerational family history of AF

Additional considerations:

• Positive family history of AF in a first-degree relative ≤65 years is associated with: (a) ~2× relative risk of AF development in unaffected relatives; (b) increased risk of arrhythmia recurrence post-ablation; (c) higher likelihood of requiring permanent pacemaker or ICD
• Thorough 3-generation family history should be obtained in all newly diagnosed AF patients

Genetic Variants and Catheter Ablation Outcomes

• 4q25 rs2200733 (most consistent finding): Associated with reduced arrhythmia-free survival post-RFCA and increased likelihood of AAD therapy post-ablation across multiple cohorts (Vanderbilt AF Registry, Caucasian population, meta-analyses)
• rs10033464 (also at 4q25): Associated with increased LA diameter; conflicting data on ablation outcomes — significant in some European cohorts and meta-analyses, not others (Turkish population)
• Other SNPs with ablation outcome associations:
  • IL6R: OR 1.84–1.92 for early/late AF recurrence post-ablation (Chinese population)
  • RANKL: HR 1.62 for AF recurrence post-first ablation (Chinese lone AF)
  • SCN10A: OR 0.36 for ablation recurrence (protective rs6795970, Chinese population)
  • CAV1 rs3807989_G: OR 4.50 for AF recurrence post-cryoballoon (Turkish population)
  • ZFHX3 rs2106216: OR 2.70 for AF recurrence in long-standing persistent AF (Korean population)
• Potential mechanism: 4q25 SNPs may increase LA scar formation and non-PV triggers for AF recurrence

Genetic Variants and Pharmacotherapy

• Rate control: AF susceptibility SNP score including 4q25 did not alter response to IV diltiazem for acute rate control in an emergency room population
• AAD rhythm control: Wildtype rs10033464 at 4q25 associated with favourable AAD response vs. variant allele carriers (Vanderbilt AF Registry)
• GENETIC-AF Trial (landmark genotype-guided RCT):
  • Population: HFrEF patients with symptomatic AF/AFL
  • Intervention: Bucindolol (non-selective beta-blocker) vs. metoprolol succinate
  • Genotype selection: ADRB1 Arg389Arg (homozygous wildtype at beta-1 adrenergic receptor)
  • Result: Bucindolol → 55% reduction in AF burden vs. metoprolol; 32% reduction in need for rhythm control strategies for recurrent AF/AFL
  • Significance: First prospective RCT demonstrating genotype-guided superiority of one beta-blocker over another in AF management

Implications for Cardiomyopathy-Associated AF

• Patients with TTN or LMNA mutations and AF should have heightened surveillance for:
  • Ventricular tachyarrhythmias (NSVT)
  • AV block
  • LV dysfunction (periodic echocardiography/CMR)
• Early family screening indicated for arrhythmia and LV dysfunction
• Referral to cardiologist with genetic cardiomyopathy expertise when genetic cardiomyopathy is suspected

Future Directions

• Development of comprehensive risk models combining common and rare variants + clinical phenotype + family history
• Genotype-informed selection of rate control, AAD, and ablation therapy
• PRS for thromboembolic/cardioembolic stroke risk stratification in AF (emerging data — prospective studies needed)
• Diversification of genetic cohorts beyond European ancestry
• Integration of whole genome sequencing with complete phenotype data in biobanks

Limitations of the Document

• Invited review — no primary data; evidence synthesis subject to selection bias
• Published in 2022, predating the 2023 ACC/AHA Class IIb recommendation for genetic testing in AF ≤45 years — guideline statements are now outdated
• Single-institution author group (Northwestern); no formal systematic review methodology
• Ablation outcome data largely from retrospective, observational studies — no prospective randomised trials specifically designed around genetic variant-stratified ablation strategy
• Evidence predominantly from European ancestry populations; heterogeneity across ancestries acknowledged but not fully addressed
• GENETIC-AF trial represents an important advance but involved a specific narrow population (HFrEF + AF + ADRB1 Arg389Arg); generalisability to broader AF population is limited

Key Concepts Mentioned

• concepts/Early-Onset-Atrial-Fibrillation — primary clinical focus; 10% yield; 5-criterion selection framework
• concepts/Genetic-Testing-in-AF — patient selection, clinical integration, limitations
• concepts/Catheter-Ablation-AF — 4q25 SNPs and ablation outcomes; mechanism of non-PV trigger formation
• concepts/Atrial-Myopathy-in-HCM — TTNtv in familial AF with no structural change; atrial myopathy concept

Key Entities Mentioned

• entities/TTN — TTNtv in 25% familial DCM; AF preceding structural cardiomyopathy; no LV dysfunction at AF diagnosis in familial AF cohort
• entities/LMNA — laminopathies associated with higher AF rates; heightened VA/AV block surveillance
• entities/SCN5A — AF in lone AF and structural heart disease; LQT3 and Brugada overlap
• entities/KCNQ1 — GOF → early AF with normal QTc + LV dilation; LOF → LQT1
• entities/Atrial-Fibrillation — genetic architecture, testing framework, treatment outcomes
• entities/DCM — TTN/LMNA cardiomyopathy–AF overlap; surveillance for VA/LV dysfunction

Wiki Pages Updated

• wiki/sources/genetic-af-dxmx-jce-2022.md — created (this page)
• wiki/wikiindex.md — updated
• wiki/concepts/Genetic-Testing-in-AF.md — updated (5-criterion testing framework; GENETIC-AF trial; 4q25 ablation outcome data)
• wiki/concepts/Catheter-Ablation-AF.md — updated (genetic modifiers of ablation outcome)
• wiki/entities/TTN.md — updated (GENETIC-AF context; familial AF with no structural change at diagnosis)